{
  "trial_id": "NCT01383759",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Age > or = to 18",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "New diagnosis of MIDD or AL amyloidosis based on pathologic findings confirmed at Memorial Sloan Kettering Cancer Center.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Patients must show the ability to understand the investigational nature of the treatment and to give voluntary informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Female subject is either postmenopausal for at least 1 year before the screening visit, is surgically sterilized or if they are of childbearing potential, agree to practice 2 effective methods of contraception from the time of signing the informed consent form through 30 days after the last dose of bortezomib, or agree to completely abstain from heterosexual intercourse.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Male subjects, even if surgically sterilized (i.e., status post-vasectomy) must agree to 1 of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourse.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Adequate organ function defined as follows: Absolute granulocytes > 1,000/mm3 and platelets > 70,000/mm3, unless low granulocyte and platelets counts are due to multiple myeloma; total bilirubin < 1.5 ULN; AST, ALT, and alkaline phosphatase < 3 times upper limit of laboratory normal; LVEF > 50% by MUGA or ECHO (the method used at baseline must be used for later monitoring); DLCO > 50 % confirmed at MSKCC; elevated creatinine is not a contraindication to enrollment",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Performance status (ECOG) < or = to 2",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Patient has received other investigational drugs with 14 days before enrollment",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Prior initial treatment chemotherapy for MIDD, AL amyloidosis or multiple myeloma with the exception of one cycle of high dose dexamethasone",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "notes": "Patient has a history of recurrent disease and systemic amyloidosis. She is on hemodialysis for ESRD.",
  "_meta": {
    "topic_id": "17",
    "trial_id": "NCT01383759",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}